Pages

Sunday, July 18, 2021

Weekend summary on your portfolio Delacrox

Last week change: AA -4.60%, AGR +0.52%, ARNC -0.84%, BKR -2.92%, BMY -0.19%, CNL n/a, CTVA -1.44%, CVX -2.65%, D +1.34%, DD -4.20%, DE -1.04%, DOW -3.07%, DUK +0.79%, FE +0.99%, HE -0.60%, HWM -2.31%, IBM -1.10%, JNJ -0.16%, K +0.58%, KO -0.07%, MBKL 0.0, MMM -1.59%, PFE +0.65%, PG +0.97%, PSX -3.49%, RTX -1.71%, T -0.32%, TE n/a, VTRS -0.86%, WNR n/a, XOM -2.77%

Add or remove stocks or check stock prices now.

EXCLUSIVE:  5 Precursors to Triple-Digit Gains

The key to finding million-dollar stocks is surprisingly simple… But often neglected. Our Top Rated Stocks system used it to identify a "Very Bullish" stock that's among the top performers of 2021. Stay focused on these 5 factors - and you could reach your investing goals in record time.  Get 3 top buys now »

Breaking News

IBM IBM Q2 2021 Earnings Preview

PFE Merck wins FDA approval for new pneumonia vaccine

Related Analysis

T Sand In My Shoes - June Update by Brian Soule

DUK, PG Dividend Champion And Contender Highlights: Week Of July 18 by Justin Law

CTVA, DD FMAT: Materials Dashboard For July by Fred Piard

XOM Early Warning Signs Developing For Stocks by Income Generator

BMY Red Hot Inflation: Healthcare Stocks You Can Buy by Limelight Alpha Management Partners

T Apple Investors Should Start Tuning Out Skepticism Around Streaming Strategy by The Entertainment Oracle

Press Releases

PFE ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19 (Business Wire)

PFE ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs (Business Wire)


Download Seeking Alpha for your Phone or Tablet
     

Why are you receiving this? You subscribed to Daily Portfolio Summary on your portfolio Delacrox at Seeking Alpha. Unsubscribe here.

To ensure you receive these emails in the future, please add account@seekingalpha.com to your address book, contacts or list of safe senders.

Sent by Seeking Alpha, 52 Vanderbilt Avenue, 13th floor, New York, NY 10017